Teva Pharmaceutical Industries (NYSE:TEVA) Upgraded by Argus to “Buy”
Argus upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from a hold rating to a buy rating in a research report report published on Wednesday, MarketBeat.com reports. Argus currently has $20.00 price target on the stock. A number of other brokerages have also recently weighed in on TEVA. Bank of America lifted their […]
More Stories
World News in Brief: North Gaza under siege, aid to millions in Syria, tensions in Mozambique
The UN aid coordination office (OCHA) on Tuesday reported further attacks on displacement shelters in Gaza which have been ongoing...
Destra Multi-Alternative Fund (NYSE:DMA) Sees Large Increase in Short Interest
Destra Multi-Alternative Fund (NYSE:DMA – Get Free Report) was the recipient of a significant growth in short interest in the...
Bancroft Fund Ltd. (NYSEAMERICAN:BCV) Sees Large Growth in Short Interest
Bancroft Fund Ltd. (NYSEAMERICAN:BCV – Get Free Report) saw a significant increase in short interest in the month of December....
Dominari Holdings Inc. (NASDAQ:DOMH) Short Interest Update
Dominari Holdings Inc. (NASDAQ:DOMH – Get Free Report) was the recipient of a large growth in short interest in the...
Global X Renewable Energy Producers ETF (NASDAQ:RNRG) Sees Significant Increase in Short Interest
Global X Renewable Energy Producers ETF (NASDAQ:RNRG – Get Free Report) saw a large growth in short interest during the...
Raytech Holding Ltd. (NASDAQ:RAY) Sees Significant Increase in Short Interest
Raytech Holding Ltd. (NASDAQ:RAY – Get Free Report) was the target of a large increase in short interest in December....